ClinicalTrials.Veeva

Menu

Patient Perception Study for AL-4943A

Alcon logo

Alcon

Status and phase

Completed
Phase 4

Conditions

Allergic Conjunctivitis

Treatments

Drug: AL-4943A

Study type

Interventional

Funder types

Industry

Identifiers

NCT01294969
SMA-10-15

Details and patient eligibility

About

To evaluate patient perceptions of Al-4943 in subjects with allergic conjunctivitis previously treated with a topical ocular anti-allergy leukotriene-release inhibitor medication.

Enrollment

47 patients

Sex

All

Ages

12+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • History of allergic conjunctivitis within last 24 months
  • Active signs and symptoms of ocular allergies

Exclusion criteria

  • Severe or serious ocular condition, ocular surgical intervention, ocular infection

Trial design

Primary purpose

Treatment

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

47 participants in 1 patient group

AL-4943A
Experimental group
Description:
One drop per day in both eyes
Treatment:
Drug: AL-4943A

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems